Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederick R Appelbaum

Showing results (301-310 of 339) with videos related to

Pageof 34
Sort By:
Blood|August 1, 2002
Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndromeH Joachim Deeg, Barry Storer, John T Slattery, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 30, 2009
Acute myeloid leukemiaMargaret R O'Donnell, Frederick R Appelbaum, Steven E Coutre, et al.
British Journal of Haematology|July 9, 2013
A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemiaFabiana Ostronoff, Megan Othus, Hagop M Kantarjian, et al.
Blood|November 30, 2016
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelHartmut Döhner, Elihu Estey, David Grimwade, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2011
Acute myeloid leukemiaMargaret R O'Donnell, Camille N Abboud, Jessica Altman, et al.
Blood|August 16, 2003
Allogeneic hematopoietic stem cell transplantation for myelofibrosisH Joachim Deeg, Theodore A Gooley, Mary E D Flowers, et al.
Blood|August 12, 2024
Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendationsHartmut Döhner, Courtney D DiNardo, Frederick R Appelbaum, et al.
Leukemia|August 3, 2022
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trialNikolaus Jahn, Ekaterina Jahn, Maral Saadati, et al.
Blood|July 7, 2022
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELNHartmut Döhner, Andrew H Wei, Frederick R Appelbaum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2017
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117Mikkael A Sekeres, Megan Othus, Alan F List, et al.
Pageof 34

Showing results (301-310 of 339) with videos related to

Sort By:
Pageof 34
Blood|August 1, 2002
Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndromeH Joachim Deeg, Barry Storer, John T Slattery, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 30, 2009
Acute myeloid leukemiaMargaret R O'Donnell, Frederick R Appelbaum, Steven E Coutre, et al.
British Journal of Haematology|July 9, 2013
A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemiaFabiana Ostronoff, Megan Othus, Hagop M Kantarjian, et al.
Blood|November 30, 2016
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelHartmut Döhner, Elihu Estey, David Grimwade, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2011
Acute myeloid leukemiaMargaret R O'Donnell, Camille N Abboud, Jessica Altman, et al.
Blood|August 16, 2003
Allogeneic hematopoietic stem cell transplantation for myelofibrosisH Joachim Deeg, Theodore A Gooley, Mary E D Flowers, et al.
Blood|August 12, 2024
Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendationsHartmut Döhner, Courtney D DiNardo, Frederick R Appelbaum, et al.
Leukemia|August 3, 2022
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trialNikolaus Jahn, Ekaterina Jahn, Maral Saadati, et al.
Blood|July 7, 2022
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELNHartmut Döhner, Andrew H Wei, Frederick R Appelbaum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2017
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117Mikkael A Sekeres, Megan Othus, Alan F List, et al.
Pageof 34